Study Comparing Concentrations of Bupivacaine to Reduce Rebound Pain After Total Shoulder Replacement
Led by University of Virginia · Updated on 2026-09-09
10
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effect of different concentrations of local anesthetic on rebound pain after shoulder replacement surgery. This randomized control study focuses on patients undergoing anatomic or reverse total shoulder arthroplasty and investigates whether using a lower concentration of local anesthetic reduces pain scores 24 hours after surgery. The study is conducted by the University of Virginia and is designed as a phase 4 interventional trial with double-blind randomization.
Participants will receive one of two concentrations of the drug Bupivacaine during their procedure either 10 ml of 0.5% concentration or 20 ml of 0.25% concentration, both containing the same total dosage of 50 mg. These two study groups compare a standard higher concentration against a more diluted version to assess differences in pain and other related outcomes.
During the study, participants will be monitored for various outcomes including maximum pain score 24 hours after the intervention, pain levels at 24, 48, and 72 hours, opioid use, sensory block duration, and the presence of side effects such as shortness of breath, nausea, vomiting, and persistent nerve symptoms. Questionnaires and clinical assessments will be conducted at specified timepoints up to 72 hours post-procedure to evaluate these measures. The total study duration extends until 2029, allowing for comprehensive safety and effectiveness observations.
CONDITIONS
Brief Title
Effect of Local Anesthetic Concentration on Rebound Pain
Research Team
L
Leon N Grinman, DO
B
Brett Elmore, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Concentrated Bupivacaine (0.5%, 10 ml)
Dilute Bupivacaine (0.25%, 20 ml)
What it is
A single-shot interscalene nerve block using concentrated bupivacaine (0.5% solution, 10 ml, total dose 50 mg) before shoulder replacement surgery.
A single-shot interscalene nerve block using dilute bupivacaine (0.25% solution, 20 ml, total dose 50 mg) before shoulder replacement surgery.
Role in the trial
Investigational group; tested for effect on rebound pain and analgesia with more concentrated local anesthetic.
Comparator group; tested for effect on rebound pain and analgesia with less concentrated, higher-volume local anesthetic.
Primary use
Provides surgical anesthesia and pain relief during and after shoulder replacement, with interest in effects on 'rebound pain' after block wears off.
Provides regional anesthesia and postoperative pain relief for the same procedure, with concentration/volume chosen to compare influence on block duration and rebound pain.
How it is given or performed
Single-shot interscalene block with 10 ml of 0.5% bupivacaine, administered before shoulder surgery as part of standard anesthesia procedures.
Single-shot interscalene block with 20 ml of 0.25% bupivacaine, using the same total dose as the other group, before shoulder surgery.
Evidence status
Investigated in ongoing clinical trials, with previous studies supporting interscalene bupivacaine use for shoulder procedures. Effect on rebound pain specifically at this concentration is still under study.
Investigated in ongoing clinical trials; previous research shows changing concentration and volume influences nerve block duration, but the role in rebound pain prevention is under active study.
Important limitations
Effect on rebound pain is not yet established, and outcomes may differ according to individual patient factors. True impact on opioid use, block duration, and unwanted side effects remains under investigation.
The benefit for reducing rebound pain with dilute bupivacaine is not proven, and outcomes such as duration of pain control and sensory block need further research in this context.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Patients undergoing anatomic or reverse total shoulder replacement
Adults aged 18 years or older
Any gender
Any race
You will not qualify if you...
Chronic pain diagnoses including substance or opioid use disorder, complex regional pain syndrome, or fibromyalgia
Daily persistent opioid use for 3 months prior to surgery
Allergy to local anesthetics or NSAIDs
Respiratory diseases such as untreated sleep apnea, COPD, restrictive lung disease, or diaphragm dysfunction
Body mass index (BMI) greater than 40
Pre-existing nerve injury in the affected arm
Kidney function with GFR less than 60
Contraindications to NSAIDs
Inability to follow up after surgery
Revision shoulder surgery
Patients requesting nerve block as primary anesthesia instead of general anesthesia
Need or request for brachial plexus catheter or liposomal bupivacaine
Vulnerable populations including pregnancy and incarceration
Non-English speakers
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Single treatment at surgery
Participants receive one of two doses of Bupivacaine during shoulder replacement surgery to study its effect on rebound pain.
Assessments at 24, 48, and 72 hours post-surgery
Follow-up
Duration - Up to 3 days
Participants are monitored for pain scores, opioid use, sensory block duration, and possible side effects up to 72 hours after surgery.
Multiple assessments during the follow-up period
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Comparing Ultrasound-Guided Nerve Blocks for Pain Relief and Breathing Safety in Shoulder Surgery
Study Comparing Effects of Interscalene Block Alone Versus Combined with Superficial Cervical Block on Brain Oxygen Levels and Carotid Artery Size During Shoulder Surgery
Study Comparing Early and Delayed Rehabilitation After Reverse Total Shoulder Replacement for Proximal Humerus Fractures in Adults Aged 50 to 85
Study Comparing Concentrations of Bupivacaine to Reduce Rebound Pain After Total Shoulder Replacement
Evaluating Oral Tranexamic Acid for Short-Term Recovery After Total Shoulder Replacement Surgery
Prospective Study of Outcomes After Total Shoulder Replacement at Hospital for Special Surgery
Comparing Interscalene and Anterior Suprascapular Blocks to Epidural Analgesia for Shoulder Pain After Thoracotomy Surgery
Optimizing Pain Control After Shoulder Surgery Comparing Single-Shot Nerve Block with IV Dexamethasone to Continuous Brachial Plexus Block
Evaluating Antimicrobial Washes Versus No Treatment to Reduce Cutibacterium Acnes During Shoulder Replacement Surgery
Evaluating Nutritional Status Impact on Functional Recovery in Frail Older Adults Using Virtual Reality-Enhanced Shoulder Rehabilitation
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Reducing rebound pain severity after arthroscopic shoulder surgery under general anesthesia and interscalene block: a two-centre randomized controlled trial of pre-emptive opioid treatment compared with placebo.
Perineural dexamethasone reduces rebound pain after ropivacaine single injection interscalene block for arthroscopic shoulder surgery: a randomized controlled trial.